Suggestions

Du même auteur

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Archive ouverte | Le, Xiuning | CCSD

International audience. Abstract Purpose: Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present upda...

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

Archive ouverte | Mazieres, Julien | CCSD

International audience. Importance MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 ( MET ex14)-skipping non–small cell lung cancer (NSCLC); however, data with longer follow-u...

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Archive ouverte | Garassino, Marina, Chiara | CCSD

International audience. has a patent T-cell immunotherapy development pending; is a founder and owner of BioCytics, which is a clinical research laboratory developing T-cell immunotherapy; and has previously bought ...

Chargement des enrichissements...